JP2024038503A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2024038503A5 JP2024038503A5 JP2024011014A JP2024011014A JP2024038503A5 JP 2024038503 A5 JP2024038503 A5 JP 2024038503A5 JP 2024011014 A JP2024011014 A JP 2024011014A JP 2024011014 A JP2024011014 A JP 2024011014A JP 2024038503 A5 JP2024038503 A5 JP 2024038503A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- tumor antigen
- specific
- population
- percentage
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962845251P | 2019-05-08 | 2019-05-08 | |
| US62/845,251 | 2019-05-08 | ||
| PCT/US2020/031898 WO2020227546A1 (en) | 2019-05-08 | 2020-05-07 | T cell manufacturing compositions and methods |
| JP2021566008A JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | Ｔ細胞製造組成物および方法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Division JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | Ｔ細胞製造組成物および方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024038503A JP2024038503A (ja) | 2024-03-19 |
| JP2024038503A5 true JP2024038503A5 (https=) | 2024-05-28 |
Family
ID=73051205
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Active JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | Ｔ細胞製造組成物および方法 |
| JP2024011014A Pending JP2024038503A (ja) | 2019-05-08 | 2024-01-29 | Ｔ細胞製造組成物および方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021566008A Active JP7582971B2 (ja) | 2019-05-08 | 2020-05-07 | Ｔ細胞製造組成物および方法 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20220280621A1 (https=) |
| EP (1) | EP3965784A4 (https=) |
| JP (2) | JP7582971B2 (https=) |
| KR (2) | KR102756321B1 (https=) |
| CN (2) | CN121086984A (https=) |
| AR (1) | AR118859A1 (https=) |
| AU (1) | AU2020268397A1 (https=) |
| BR (1) | BR112021022363A2 (https=) |
| CA (1) | CA3137037A1 (https=) |
| IL (1) | IL287874A (https=) |
| MX (1) | MX2021013608A (https=) |
| PH (1) | PH12021552829A1 (https=) |
| SG (1) | SG11202112346WA (https=) |
| TW (2) | TWI777160B (https=) |
| WO (1) | WO2020227546A1 (https=) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3101122B1 (en) | 2009-08-24 | 2023-06-14 | Baylor College of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| PT2812431T (pt) | 2012-02-09 | 2019-10-18 | Baylor College Medicine | Pepmixes para gerar ctls multivirais com larga especifidade |
| JP6999941B2 (ja) | 2015-09-18 | 2022-02-10 | ベイラー カレッジ オブ メディスン | 病原体からの免疫原性抗原同定および臨床的有効性との相関 |
| CA3081840A1 (en) | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| KR20210040355A (ko) * | 2018-06-19 | 2021-04-13 | 바이오엔테크 유에스 인크. | 네오항원 및 이의 용도 |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
| EP4114400A4 (en) * | 2020-03-05 | 2023-10-18 | Exuma Biotech Corp. | Methods and compositions for the delivery of modified lymphocyte aggregates |
| US12365871B2 (en) | 2020-04-28 | 2025-07-22 | Lyell Immunopharma, Inc. | Methods for culturing cells |
| US20230374455A1 (en) * | 2020-08-13 | 2023-11-23 | Biontech Us Inc. | T cell manufacturing compositions and methods |
| US11948694B2 (en) * | 2021-05-12 | 2024-04-02 | Merative Us L.P. | Controlling compartmental flows in epidemiological modeling based on mobility data |
| US12062456B2 (en) | 2021-05-27 | 2024-08-13 | Merative Us L.P. | Hypothetical scenario evaluation in infectious disease dynamics based on similar regions |
| IL312121A (en) * | 2021-10-15 | 2024-06-01 | Biontech Us Inc | T cell manufacturing compositions and methods |
| WO2023159088A1 (en) * | 2022-02-15 | 2023-08-24 | Marker Therapeutics, Inc. | Compositions and methods for antigen-specific t cell expansion |
| IL321246A (en) * | 2022-12-09 | 2025-08-01 | Biontech Us Inc | Compositions and methods for producing T cells |
| WO2024151124A1 (ko) * | 2023-01-12 | 2024-07-18 | 주식회사 이뮤노맥스 | 항암능이 우수한 기억 t 세포 유래 면역세포치료제의 제조방법 |
| CN117417886B (zh) * | 2023-10-20 | 2024-05-14 | 广东壹加再生医学研究院有限公司 | 一种负载肿瘤抗原的树突状细胞激活的t淋巴细胞的培养方法 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7276478B2 (en) * | 2003-09-25 | 2007-10-02 | Zymogenetics, Inc. | Methods of treating autoimmune diseases using IL-21 |
| WO2006110582A1 (en) * | 2005-04-08 | 2006-10-19 | Xcyte Therapies, Inc. | Compositions and methods for the treatment of burns and sepsis |
| DE102005046490A1 (de) * | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| US9809797B2 (en) * | 2007-10-03 | 2017-11-07 | National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology | Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression |
| EP2749639B1 (en) * | 2012-02-10 | 2016-10-12 | Hakushinkouseikai Foundation | Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine |
| RU2763795C2 (ru) * | 2014-04-23 | 2022-01-11 | Джуно Терапьютикс, Инк. | Способы выделения, культивирования и генетической инженерии популяций клеток иммунной системы для адоптивной терапии |
| DE102015214780A1 (de) * | 2015-08-03 | 2017-02-09 | Continental Automotive Gmbh | Verfahren zur Erkennung fehlerhafter Komponenten eines Kraftstoffeinspritzsystems |
| AU2016306408B2 (en) * | 2015-08-10 | 2021-02-11 | Toray Industries, Inc. | Immune inducer |
| EP3347051A4 (en) * | 2015-09-10 | 2019-04-24 | Affigen, Inc. | SEQUENCING SELECTING TUMOR THEROSTICAS |
| WO2017059557A1 (en) * | 2015-10-09 | 2017-04-13 | Peking University | Methods for enhancing in vivo persistence and efficacy of exogenously administered t cells, genetically modified t cells and method and method of use |
| AU2018337960B2 (en) * | 2017-09-20 | 2025-08-14 | Neximmune, Inc. | Cell compositions comprising antigen-specific T cells for adoptive therapy |
| CA3081840A1 (en) * | 2017-11-08 | 2019-05-16 | Neon Therapeutics, Inc. | T cell manufacturing compositions and methods |
| TWI777160B (zh) * | 2019-05-08 | 2022-09-11 | 美商百歐恩泰美國公司 | T細胞製備組合物及方法 |
-
2020
- 2020-05-05 TW TW109114957A patent/TWI777160B/zh active
- 2020-05-05 TW TW111130596A patent/TWI867324B/zh active
- 2020-05-05 AR ARP200101269A patent/AR118859A1/es unknown
- 2020-05-07 KR KR1020217040167A patent/KR102756321B1/ko active Active
- 2020-05-07 CA CA3137037A patent/CA3137037A1/en active Pending
- 2020-05-07 US US17/609,705 patent/US20220280621A1/en active Pending
- 2020-05-07 AU AU2020268397A patent/AU2020268397A1/en active Pending
- 2020-05-07 CN CN202511339181.5A patent/CN121086984A/zh active Pending
- 2020-05-07 JP JP2021566008A patent/JP7582971B2/ja active Active
- 2020-05-07 PH PH1/2021/552829A patent/PH12021552829A1/en unknown
- 2020-05-07 SG SG11202112346WA patent/SG11202112346WA/en unknown
- 2020-05-07 KR KR1020247036158A patent/KR20240161214A/ko active Pending
- 2020-05-07 CN CN202080050310.8A patent/CN114096261B/zh active Active
- 2020-05-07 BR BR112021022363A patent/BR112021022363A2/pt unknown
- 2020-05-07 WO PCT/US2020/031898 patent/WO2020227546A1/en not_active Ceased
- 2020-05-07 EP EP20801696.4A patent/EP3965784A4/en active Pending
- 2020-05-07 MX MX2021013608A patent/MX2021013608A/es unknown
-
2021
- 2021-11-07 IL IL287874A patent/IL287874A/en unknown
-
2024
- 2024-01-29 JP JP2024011014A patent/JP2024038503A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024038503A5 (https=) | ||
| Maus et al. | HLA tetramer-based artificial antigen-presenting cells for stimulation of CD4+ T cells | |
| Saggau et al. | Autoantigen-specific CD4+ T cells acquire an exhausted phenotype and persist in human antigen-specific autoimmune diseases | |
| Sun et al. | MHC class II restricted neoantigen: a promising target in tumor immunotherapy | |
| JP2024041873A5 (https=) | ||
| JP2021502414A5 (https=) | ||
| JP2025061689A (ja) | 変異型ｒａｓを標的とするための組成物および方法 | |
| JP5634415B2 (ja) | 腫瘍の治療のための細胞治療方法 | |
| EP2899269B1 (en) | Method for cloning t cell receptor | |
| CN109715788A (zh) | 用于免疫疗法的t细胞组合物 | |
| TW201819628A (zh) | 使用具有工程化穩定表現內源性foxp3基因之cd4 t細胞治療自體免疫疾病的方法 | |
| Toso et al. | MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation | |
| Ajith et al. | Humanized mouse model as a novel approach in the assessment of human allogeneic responses in organ transplantation | |
| Bacsi et al. | Complexes of heparin and platelet factor 4 specifically stimulate T cells from patients with heparin-induced thrombocytopenia/thrombosis | |
| JP2022527364A (ja) | Ｔ細胞受容体遺伝子アセンブリのための組成物及び方法 | |
| JP2023017853A (ja) | 新規な癌抗原及び方法 | |
| Boehm et al. | Concurrent vaccination with two distinct vaccine platforms targeting the same antigen generates phenotypically and functionally distinct T-cell populations | |
| JP2022540396A (ja) | 新規な癌抗原及び方法 | |
| JP2022539157A (ja) | 新規な癌抗原及び方法 | |
| Zhang et al. | A polyclonal anti‐vaccine CD4 T cell response detected with HLA‐DP4 multimers in a melanoma patient vaccinated with MAGE‐3. DP4‐peptide‐pulsed dendritic cells | |
| Fontaine et al. | Regulatory T cells constrain the TCR repertoire of antigen‐stimulated conventional CD4 T cells | |
| JP6878544B2 (ja) | がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法 | |
| Gallard et al. | Tracking T cell clonotypes in complex T lymphocyte populations by real-time quantitative PCR using fluorogenic complementarity-determining region-3-specific probes | |
| AU2024275280A1 (en) | T cell receptors that bind presented hpv16-, mart1-, cmv-, ebv-, or influenza- peptides | |
| JP2003521936A (ja) | 樹状細胞ハイブリッドによって活性化される細胞傷害性ｔリンパ球 |